hsa-mir-607: Hsa-mir-607 is an intergenic microRNA (miRNA) that has been found to be underexpressed in extracellular vesicles (EVs) from patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) compared to healthy controls (HCs) [PMC7005890]. This miRNA has been associated with various biological processes and diseases, including neuropsychiatric and neurodegenerative diseases [PMC5776763]. It is also implicated in the regulation of genes within the TruSight Myeloid Sequencing panel, forming pairs with 13 genes [PMC7851519]. In cancer research, hsa-mir-607 has been linked to poor overall survival in cervical squamous cell carcinoma (CESC), highlighting its potential as a prognostic biomarker [PMC7333649]. Additionally, hsa-mir-607 is predicted to interact with circular RNAs such as circ_0088300 and is involved in complex regulatory networks, having a significant number of gene targets within a coexpression network [PMC9461120]. It also appears to co-regulate genes such as PIGK and ITGB1, suggesting its role in cellular processes that could be relevant for cancer progression or other pathologies [PMC9669594]. Despite its underexpression in ME/CFS EVs, hsa-mir-607's broader implications across various diseases underscore its importance for further research into miRNA-based diagnostics and therapeutics.